

***Dr Marc Antoine Jean-Gilles – CHUV,  
cardiologie***

**Prix Santé Cardiovasculaire 2024**

**Prix Action**

***«A step towards a more  
personalized secondary  
cardiovascular prevention»***

*Hôtel de la Paix, Lausanne - 26.09.2024*



# Risk estimation in patients with established atherosclerotic cardiovascular disease: comparison of 4 and validation of 2 risk prediction models for recurrent cardiovascular events in a Swiss multicentric cohort

*Marc Jean-Gilles, Cédric Follonier, Orestis Efthimiou, David Carballo, David Nanchen Lorenz Räber Roland Klingenberg Stephan Windecker, Thomas F. Lüscher, Christian M. Matter, Olivier Muller, Nicolas Rodondi, François Mach, **Baris Gencer***

# Background, objective and endpoints

- Cardiovascular diseases: a significant burden on Swiss Healthcare System, **leading cause of death and third leading cause of hospitalisation in 2022<sup>1</sup>**
- Overall long-term cardiovascular risk can vary across individuals, **even in secondary prevention population**
- Unlike primary prevention scores, secondary risk prediction scores are **poorly known and underutilized**



Objective: “To evaluate the **performance** of four secondary risk prediction scores and identify **the most suitable one** for treatment and follow up of **Swiss patients with coronary artery disease**”

1° endpoint : Major Adverse Cardiovascular Event (MACE) at 1 and 5 years

2° endpoint : components of 1° endpoint; coronary revascularisation; unstable angina at 1 and 5 years

# Potential Implications – Swiss Perspective

- SPUM-ACS consortium: **≈ 7000 Swiss patients, multicentric cohort, 25% of patients from Lausanne**
- **Enhanced individualized risk assessment and improved decision-making** in the Swiss secondary prevention population
- Identifying **potential gaps in existing risk scores** and the need for a **“tailor made” risk score** specifically for the **Swiss population with coronary artery disease**

# Potential Implications – Global Perspective

Improving the use of secondary prevention scores: **A Paradigm Shift**

From «**class risk**» assessment to a more «**individualized risk**» approach, **even in secondary prevention populations**

- **Identifying very high-risk patients** who will **benefit the most** (intensification of available therapies)
- **Optimizing resource allocation** (low-income countries and cost of emerging therapies)
- **Enhancing communication** between healthcare providers and patients

A step forward in the development of **personalized cardiovascular prevention**



MJG, Lanzarote, 11.03.2024



**Thank you for your attention !**